TAPI (Teva Active Pharmaceutical Ingredients) is the leading manufacturer of APIs in the world today with over 75 years of experience and around $750 million in third party sales. The company currently holds the industries largest portfolio of over 300 APIs.
TAPI employs over 5,000 professionals worldwide with its headquarters located in Israel next to Tel Aviv. Production facilities are located in Italy, Hungary, the Czech Republic, Croatia, Israel, India, China, Mexico, Puerto Rico and the United States.
The company’s Research & Development unit currently comprises over 750 scientists who specialize in the fields of chemical synthesis, fermentation, high potency APIs, plant extraction, synthetic peptides, vitamin D derivatives and prostaglandins.
Dr. Reddy’s Laboratories Ltd
Dr. Reddy’s is another leading manufacturer of APIs with over 60 APIs that are used for drug manufacture, diagnostic kits, critical care and biotechnology products. As of 2006, Dr. Reddy’s Laboratories reached over $500 million in revenue of which 75% came from their APIs and branded formulations.
By 2007, Dr. Reddy’s had 6 FDA plants producing active pharmaceutical ingredients in India alone. Currently, Dr. Reddy’s deals with and manages all the processes from the development and manufacture of the API to the submission of the finished dosage dossiers to the regulatory agencies.
Aurobindo is a fully integrated global pharmaceutical company. The API business is fully supported by technologically advanced API research and development infrastructure that develops new products and is involved with them right up until their delivery to market.
Aurobindo has a product list of over 200 APIs with five of their manufacturing facilities inspected by reputed regulatory agencies such as the FDA and MHRA.
Cipla was one of the first companies to fully develop and manufacture Active Pharmaceutical Ingredients and in this way helped lay the foundations down for the pharmaceutical industry in India.
Today they manufacture over 200 generic APIs covering a wide range of therapeutic categories, reaching out to more than 170 countries worldwide. Cipla have three manufacturing facilities located in India that are approved by reputable regulatory agencies.
Sandoz is a subsidiary of Novartis, a multinational pharmaceutical company. As of 2011, Sandoz was the world’s second largest generic drug company with total revenue of nearly $11 billion. Sandoz offer around 20 API products.
Ranbaxy is a leading pharmaceutical company that supplies APIs to leading innovators and generic companies in more than 65 countries. They currently have four API manufacturing facilities across India where they produce just over 100 API products.
Sun Pharma’s API program began in 1995 – today they manufacture APIs at 9 different plants including locations such as Hungary, Israel and the U.S. They have expanded their API manufacturing and currently produce over 200 APIs including warfarn, carbamazepine and clorazepate.